OTC Eye Treatment Label Centers on Peptides, Retinol, and a Narrow Safety Message
DailyMed’s current label for FERMAGLOW INSTANT ANTI AGING WRINKLE EYE TREATMENT SYRINGE places the product in a familiar but tightly regulated corner of over-the-counter skin care: a topical eye-area cream marketed for wrinkle correction and prevention. The label frames its use around the concerns that drive most cosmetic eye-product purchases — deep lines, fine lines, puffiness, and dark circles — while pairing those claims with a more clinical list of active ingredients and clear cautions for external use only.
The product is identified as a human OTC drug with topical and transdermal administration. It is packaged as a 30 g prefilled plastic syringe, a delivery format that suggests controlled dispensing rather than a traditional jar or tube. The listed manufacturer is Guangzhou Meijiao Medical Biotechnology Co., Ltd., and the label carries the NDC 87036-040-01.
The formulation is built around a cluster of ingredients commonly used in cosmetic dermatology and periocular skin care. The active ingredient panel lists acetyl hexapeptide-8, dipeptide-2, palmitoyl tetrapeptide-7, retinol, and hyaluronic acid. Each is assigned a purpose on the label: anti-wrinkle, anti-aging, or hydrating. The concentration table gives the strongest quantitative window into the product’s design, with retinol at 0.045 g in 30 g, hyaluronic acid at 0.045 g in 30 g, acetyl hexapeptide-8 at 0.15 g in 30 g, dipeptide-2 at 0.36 g in 30 g, and palmitoyl tetrapeptide-7 at 0.006 g in 30 g.
One sentence captures the practical reality of the label: this is not a single-ingredient eye cream, but a layered cosmetic-pharmacologic blend.
The ingredient mix is notable because it combines barrier support, hydration, and retinoid-driven renewal in one formulation. Hyaluronic acid and sodium hyaluronate are positioned to draw and hold water in the skin, which can improve the look of fine creasing by increasing surface hydration. Retinol and retinyl palmitate point in a different direction, toward accelerated skin turnover and a cosmetic anti-aging effect, although the trade-off in this periocular zone is a higher risk of irritation than with bland moisturizers. The peptide components — acetyl hexapeptide-8, dipeptide-2, and palmitoyl tetrapeptide-7 — are commonly used in cosmetic formulations that aim to soften the appearance of expression lines or soothe the look of tired skin, especially where swelling and under-eye fatigue are part of the marketing rationale.
The inactive ingredient list reinforces that broader design. Water, sodium silicate, magnesium aluminum silicate, xanthan gum, caprylic/capric triglyceride, avocado oil, coffee seed oil, cucumber fruit extract, rhodiola rosea root, white truffle extract, saccharomyces cerevisiae extract, mica, titanium dioxide, and dimethylaminoethanol tartrate all appear in the formulation. Some ingredients are plainly functional — thickeners, stabilizers, emollients, texture modifiers — while others are selected for their cosmetic story as much as for any measurable biologic effect. In real-world use, that matters because the visible finish of an eye product often depends as much on film formation and light reflection as on any molecular activity deeper in the skin.
The directions are straightforward: apply to clean, dry skin 15 minutes before sun exposure, then reapply every 2 hours or after swimming, sweating, or towel drying. Those instructions place the product in a sunscreen-like behavioral framework even though the label excerpt centers more on anti-aging than photoprotection. For an eye-area product, that timing is not a minor detail. Periocular skin is thin, sensitive, and frequently exposed to sunlight, so any topical product that includes retinol must be used with caution because irritation and photosensitivity can complicate routine use.
Safety language on the label is brief but direct. The cream is for external use only, should be kept away from the eyes, and should be discontinued if irritation occurs. The product is to be kept out of reach of children, and if swallowed, immediate medical help or Poison Control contact is advised. For a cosmetic-style OTC product with retinol in the formula, those warnings are clinically routine but still important, especially when the target anatomy is as unforgiving as the eyelid and infraorbital skin.
Storage instructions are also specific: keep the container tightly closed and store at 15–40°C, away from extreme heat or direct sunlight. That guidance is consistent with a formulation that includes multiple sensitive cosmetic actives and a prefilled delivery device. Heat and light can degrade certain ingredients or alter the product’s texture, and a tightly sealed container reduces the chance of contamination or evaporation over time.
The label’s marketing category is listed as OTC Monograph Drug, with a marketing start date of 11/18/2025 and a packaging start date of 10/01/2026. Those dates place the product within the current DailyMed record rather than a long-established dermatologic standard. For clinicians, pharmacists, and consumers alike, the most relevant point is simpler than the packaging chronology: the label presents a cosmetic-leaning eye treatment with a familiar anti-aging ingredient stack, but it also makes the limits of use plain by emphasizing external application and irritation precautions.
A final clinical reading is difficult to avoid: the product’s claims are broad, while the safety instructions are narrow. That tension is common in the eye-care aisle, where consumer expectations often run ahead of what a topical peptide-retinol blend can reliably deliver, especially on thin, reactive skin.